

Figure 1



Figure 2

Reactivity of MAb B6.1 against PS76-carrier protein conjugates



Figure 3

C. albicans mannan inhibits MAb B6.1 binding to PS76-KLH conjugate



PS76-KLH coated ELISA wells incubated with or without antibody plus 2ME extract

Figure 4

Figure 5



Dots 1, 2 - normal mouse serum; Dots 3-10 - serum from peptide-immunized mice; Odd dots - IgG detection; Even - IgM detection

Figure 6

Immunization with peptide mimotopes induces anti-*Candida* carbohydrate antibodies in mice



Absorbance = OD_{490nm} (Ab+2ME extract) - OD_{490nm} (Ab + irrelevant CHO)

Microtiter plate wells were coated with 2ME extract or an irrelevant carbohydrate. Mice were immunized with synthetic peptide, branched synthetic peptide, peptide carrier protein conjugates, or phage-displayed peptide mimotopes.



Carolyn - I need to see the gels - we found the sequence. Suzane

Figure 7



Fig 4.


800
600
400
200
0
Kidney cfu (10^3/g)
pAb
B6.1
B6
DPBS

B


B6.1
B6
DPBS
10
8
6
4
2
0
Survivors
0
10
20
30
40
50
60
70
Days

Fig ~~8~~ 9



Fig 8

Disseminated Candidias By Survival Time surements. Therapeutic effect of MAb B6.1 on candida ected mice (one hour infection)



Fig 4

11

Therapeutic effect of MAb B6.1 on candidal infected mice

(one hour infection)



Fig 8
12

Prophylactic effect of MAb B6.1 on mice to vulvovaginal candidiasis



Fig 6
13

Prophylactic effect of candidal MAbs on mice to vulvovaginal candidiasis



Fig 7.
14

Effect of active immunization with L-adhesion to mice against vulvovaginal candidiasis



Fig 8/15

L = liposome

L02ME = liposome-2ME raccine prep. Animals received 0.2 ml i.v. (178mg 2ME in 0.2ml) weekly for 5 weeks. Estiadiol was given subcu, 72 h later *C. albicia* ($5x10^5$) gives intravaginally, 48 h after infection vaginal cfu determined.

Proposed structure of the phosphonennan complex (PMC)-in this case, n-linkage to cell wall protein is shown.

Fig 9.16



Shibata, et al. J. Biol. Chem. 270: 1113-1995


acid labile
acid stable
A
B
C
D
VI
VII
V
IV
III
II
I
Absorbance at 490 nm
Number of fraction
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0
10
20
30
40
50
60
70
80

Fig 10



Mass spec results

Fig H
18



Fig 3

dimension H-nmv of B6.1 epitope



Fig 13

2-DNMR of B6.1 epitope

Fig 21

file name: 110596
Therapeutic effect of liposome-2ME (L-adh) as a vaccine source on mice* against vulvovaginal candidiasis.



*Animals were infected with C. *albicans* one hr before ~~antibody treatment~~ vaccination

** Mice were intravaginally infected with *Candida albicans* (5 x 10^5/mouse) 1 hr before i.v. vaccine treatment. Seven days after the infection, vagina areas were collected, and cfu in the areas were measured.

Fig 15 22

file name: 091396A
Therapeutic effect of MAb B6.1 on mice* against vulvovaginal candidiasis.



*Animals were infected with *C. albicans* one hr before antibody treatment.

T=0 5×10^5 /10μl IVg.
T= 1h MAb B6.1 30μl undil/1/4 1280, 3.5 mg/ml
T= 24h " " 10μl
T= 48h cfu

Fig. 8 46 23

file name: 101296
Therapeutic effect of MAb B6.1 & B6 on mice* against vulvovaginal candidiasis.



*Animals were infected with *C. albicans* four hrs before first antibody treatment. 7d/g

T=0 : infect 5×10^5 ivg

T=4 h MAb 30µl ivg MAb B6.1 1280 : 3.5 mg/ml. MAb B6 640, 3.5 mg/ml

T=24 h " 10µl

T=48 h cfu

File name: 100296

Purification of 2ME-BSA by a sephacryl-S-300 column

(Fig. X)



File name: 101196a
Purification of 2ME-BSA by a sephacryl-S-300 column

(Fig. 18)

void volume = 80 ml
flow rate = 16 ml/hr
collection = 50 drops/tube (1.77 ml/tube)